Radiopharm Theranostics (Radiopharm Theranostics) Accumulated other comprehensive income (loss) : $9.51 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Radiopharm Theranostics's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $9.51 Mil.

Radiopharm Theranostics's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2022 ($6.45 Mil) to Jun. 2023 ($6.95 Mil) and increased from Jun. 2023 ($6.95 Mil) to Dec. 2023 ($9.51 Mil).

Radiopharm Theranostics's annual Accumulated other comprehensive income (loss) increased from . 20 ($0.00 Mil) to Jun. 2022 ($4.94 Mil) and increased from Jun. 2022 ($4.94 Mil) to Jun. 2023 ($6.95 Mil).

Radiopharm Theranostics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Radiopharm Theranostics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Accumulated other comprehensive income (loss) Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Accumulated other comprehensive income (loss)

4.94

6.95

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Accumulated other comprehensive income (loss)	3.83	4.94	6.45	6.95	9.51

Radiopharm Theranostics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Radiopharm Theranostics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022